CN101756968A - Novel compound antihypertensive drug - Google Patents
Novel compound antihypertensive drug Download PDFInfo
- Publication number
- CN101756968A CN101756968A CN200810155783A CN200810155783A CN101756968A CN 101756968 A CN101756968 A CN 101756968A CN 200810155783 A CN200810155783 A CN 200810155783A CN 200810155783 A CN200810155783 A CN 200810155783A CN 101756968 A CN101756968 A CN 101756968A
- Authority
- CN
- China
- Prior art keywords
- nitrendipine
- metoprolol
- compound preparation
- novel compound
- antihypertensive drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a compound preparation for curing hypertension. The compound antihypertensive drug comprises 5-20mg of nitrendipine and 5-50 mg of metoprolol. Aiming at solving the problem that currently when only one of nitrendipine and metoprolol is used clinically, in order to ensure the curative effect, the dosage of the drug is increased, which leads to obvious increase of the side effects, the invention provides a novel compound preparation. Nitrendipine and metoprolol are used together, so synergic and complementary curative effect can be produced. The novel compound antihypertensive drug enhances the tolerance of the patient, improves the compliance and reduces the dosage and the adverse reaction, and is convenient to take and cheap in price.
Description
Technical field
The present invention relates to medical technical field, disclose a kind of new compound antihypertensive drug.
Background technology
Hypertension is modal cardiovascular disease, is the great public health problem in the global range.China has 100,000,000 hypertensive patients at present approximately.The Epidemiological study result showed in 1991, and China city and rural area hypertension awareness are respectively 36% and 13%, and treatment rate is respectively 17% and 5%, and the form of hypertension prevention and control is quite severe.According to the WTO prediction, will account for 79% of China's cause of death to the year two thousand twenty noninfectious, wherein the cardiovascular diseases will account for the first place.
Treatment hypertension drug commonly used has calcium antagonist nitrendipine and beta-blocker metoprolol.
Nitrendipine (Nitrendipine), chemistry is called 2,6-dimethyl-4-(3-nitrobenzophenone)-1,4-dihydro-3,5-pyridinedicarboxylic acid methyl ethyl ester, molecular formula is C
18H
2ON
2O
6, molecular weight: 360.37, shown in the structural formula:
The nitrendipine structural formula
Nitrendipine is a kind of bihydropyridine type calcium antagonist, this product blood vessel selectivity height, expansible coronary artery and peripheral blood vessel, rapid-action, safety, gentleness, lasting; The less water-sodium retention that occurs can reduce myocardial oxygen consumption, and ischemic myocardium is had protective effect; When heavy dose of no postural hypotension the reflexive increased heart rate can appear; Take curative effect for a long time and do not subtract, no cumulative action.
Metoprolol (Hydrochlorothiazide), chemistry 1-isopropylamino-3-[by name is right-(2-methoxyethyl) phenoxy group-2-propanol L (+)-tartrate, molecular formula is (C
15H
25NO
3)
2C
4H
6O
6, molecular weight: 684.82, shown in the structural formula:
The metoprolol structural formula
Metoprolol is a kind of medicine based on β1Shen Shangxiansunengshouti retardation (heart selectivity), therefore is well suited for treatment hypertension and angina pectoris, reduces the incidence rate of myocardial infarction, the mortality rate after the reduction myocardial infarction.This product is owing to the excitement of retardance ectopia cordis pacemaker adrenoreceptor can be used for treating the tachy-arrhythmia that supraventricular tachy-arrhythmia, ventricular arrhythmia, Folium Digitalis Purpureae class and catecholamine cause.This product energy antagonism catecholamine effect can be treated the arrhythmia that hyperthyroidism causes.When therapeutic dose, this product is not obvious to the effect of shrinking bronchus and peripheral vessels, and airway resistance can be increased after indivedual case medications, can correct but add with the β1Shou Ti agonist.Be mainly used in and keep treatment, arrhythmia, hyperthyroidism after treatment hypertension, angina pectoris, the myocardial infarction.
Single treat hypertension than the strong dose thing and bring some untoward reaction sometimes with a kind of; blood pressure reduces the compensation response that triggers during as single therapy; take medicine after weak, dizzy, drowsiness, tinnitus, nauseating, vomiting, epigastric discomfort, constipation appear in regular meeting; sometimes also phenomenons such as postural hypotension, muscular spasm, insomnia can appear; though these phenomenons mostly dying away in the drug administration process continuously, also can be brought inconvenience to the patient.
Goal of the invention
Product of the present invention has overcome when using nitrendipine and metoprolol clinically now, is to guarantee that curative effect increases drug dose during singly with a medicine, causes side effect obviously to increase; During drug combination,, and use clinical medicine dose inaccurate, influence the defective of curative effect of medication because of nothing meets the pharmaceutical preparation of drug combination dosage.Nitrendipine and metoprolol two medicines share, collaborative, complementary action that curative effect has; Reduce consumption, alleviate untoward reaction, taking convenience, cheap.
Summary of the invention
The objective of the invention is to defective, a kind of compound preparation is provided at the prior art existence.
The present invention is achieved by the following technical solutions:
The hypertensive compound preparation of a kind of treatment, contain the component of following dosage:
Nitrendipine 5-20mg
Metoprolol 5-50mg
A kind of preferred as technique scheme, a kind ofly treat the component that hypertensive compound preparation contains following dosage:
Nitrendipine 10-20mg
Metoprolol 12.5-50mg
As the hypertensive compound preparation of a kind of more excellent treatment, it contains the component of following dosage:
Nitrendipine 10mg
Metoprolol 12.5mg
As the hypertensive compound preparation of a kind of more excellent treatment, it contains the component of following dosage:
Nitrendipine 10mg
Metoprolol 25mg
Beneficial effect of the present invention is: the present invention is that two kinds of antihypertensive drugs of low dose of use in conjunction are treated hypertensive, better and untoward reaction is less than single with heavy dose of wherein a kind of medicine antihypertensive effect, the treatment of associating lattice can improve efficacy of antihypertensive treatment, in and the untoward reaction that causes of different pharmaceutical, be applicable to that hyperpietic in various degree takes for a long time.
This preparation also contains a certain amount of adjuvant except that containing above two kinds of active drug; In pharmacy procedure, the addition of adjuvant can be determined according to actual needs.
The adjuvant that this preparation is commonly used has: microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, silicon dioxide, Pulvis Talci, lactose, dextrin, magnesium stearate, carboxymethylstach sodium, calcium sulfate etc.
Compound preparation of the present invention can have multiple mode, as compound recipe nitrendipine-metoprolol sheet (ordinary tablet, slow releasing tablet and other special tablets), compound recipe nitrendipine-metoprolol capsule dosage forms such as (conventional capsule, slow releasing capsule and other special capsule preparations).
Embodiment 1
A kind of compound preparation, contain following component:
Nitrendipine 10mg
Metoprolol 12.5mg
Starch 55mg
Calcium sulfate 20mg
Pulvis Talci 2mg
Magnesium stearate 0.5mg
Present embodiment can be made into compound recipe nitrendipine-metoprolol sheet, and preparation method can adopt the preparation method of common pharmaceutical preparation.
Embodiment 2
A kind of compound preparation, contain following component:
Nitrendipine 10mg
Metoprolol 25mg
Starch 40mg
Calcium sulfate 20mg
Pulvis Talci 4mg
Magnesium stearate 1mg
Present embodiment can be made into compound recipe nitrendipine-metoprolol sheet, and preparation method can adopt the preparation method of common pharmaceutical preparation.
Claims (4)
1. treat hypertensive compound preparation for one kind, contain the component of following dosage:
Nitrendipine 5-20mg
Metoprolol 5-50mg.
2. the hypertensive compound preparation of treatment according to claim 1 is characterized in that compound preparation contains the component of following dosage:
Nitrendipine 10-20mg
Metoprolol 12.5-50mg.
3. the hypertensive compound preparation of treatment according to claim 2 is characterized in that compound preparation contains the component of following dosage:
Nitrendipine 10mg
Metoprolol 12.5mg.
4. the hypertensive compound preparation of treatment according to claim 2 is characterized in that compound preparation contains the component of following dosage:
Nitrendipine 20mg
Metoprolol 12.5mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810155783A CN101756968A (en) | 2008-10-15 | 2008-10-15 | Novel compound antihypertensive drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810155783A CN101756968A (en) | 2008-10-15 | 2008-10-15 | Novel compound antihypertensive drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101756968A true CN101756968A (en) | 2010-06-30 |
Family
ID=42488450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810155783A Pending CN101756968A (en) | 2008-10-15 | 2008-10-15 | Novel compound antihypertensive drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101756968A (en) |
-
2008
- 2008-10-15 CN CN200810155783A patent/CN101756968A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104220068B (en) | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt | |
| WO2008069612A1 (en) | Pharmaceutical composition comprising amlodipine and losartan | |
| JP6068765B2 (en) | Pharmaceutical combination preparation | |
| HUE028919T2 (en) | Capsule for the prevention of cardiovascular diseases | |
| CN103230592A (en) | Composition of statin medicine and 5-methyltetrahydrofolic acid, and application thereof | |
| CN115518066A (en) | Pharmaceutical composition for treating anticoagulation and application | |
| CN101985035A (en) | Perindopril-containing compound preparation for treating hypertension | |
| CN106420738B (en) | A kind of sustained release preparation of levamlodipine or its salt and preparation method thereof | |
| CN101485659A (en) | Medicament composition of amlodipine and simvastatin as well as preparation method and application thereof | |
| CN101637442A (en) | Ranolazine oral sustained-release preparation and preparation method thereof | |
| CN101756968A (en) | Novel compound antihypertensive drug | |
| CN102058591A (en) | Levamlodipine and telmisartan compound preparation | |
| CN103800336A (en) | Composition with anti-thrombus active medicine | |
| CN101766611A (en) | Medical composition of levamlodipine or pharmaceutically acceptable salt thereof and beta-blocker and application thereof | |
| CN104758285A (en) | Novel compound anti-hypertensive drug | |
| CN101785781B (en) | Medicine combination of levoamlodipine or medicinal salt of levoamlodipine and auricularia auricula polysaccharide, and application thereof | |
| CN101756972A (en) | Compound antihypertensive medicament | |
| CN1895249A (en) | Compound preparation for treating hypentension | |
| CN101756975A (en) | Antihypertensive preparation | |
| CN101756976A (en) | Novel antihypertensive drug | |
| CN101229156B (en) | Medicine composition used for cardiovascular disorders | |
| CN101869562B (en) | Levamlodipine compound medicinal preparation | |
| CN102258523A (en) | Compound preparation for treating hypertension and its preparation method | |
| US8470363B2 (en) | Antihypertensive pharmaceutical composition | |
| CN101756994A (en) | Preparation method of compound antihypertensive preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100630 |